My concern is - if DAA treatment increases HCC risk (compared to "no treatment"), then, whether benefits of treatment outweigh its harm "in long-term perspective" or not? It seems, that data from studies look like little bit controversial...
I was diagnosed with HCV-cirrhosis in 2005 and up to now cirrhosis is compensated, and i had not events of decompensation (such as ascites, variceal bleeding, HCC etc.) My lab report (regarding to liver function) is not worse than in 2005. I feel relatively good and not sure that SVR "itself" will sufficiently improve my health... Of course, i want to achieve SVR (and already bought generics for the therapy), but possibility of increased HCC risk after DAA treatment is my main worry. Good managing of HCC requires good medical facilities, it may be difficult for many people in my country. Hope that, really, DAA treatment is not increases HCC risk.
Probably infected in 1977
2005 - diagnosed with HCV 1b, compensated F4, 15 mln viral load, ALT 320
2005-2006 - PegIFN/rib 48 weeks treatment, relapse
2016 - compensated F4, MELD 8-9, ALT 100-160
2018 - compensated F4, MELD 8, ALT 91